Pharmacological evaluation reveals subtype-selective receptor activation by novel heterocyclic GABA bioisosteres, indicating new scaffolds to probe specific GABAergic pathways.
Given the heterogeneity within the γ-aminobutyric acid (GABA) receptor and transporter families, a detailed insight into the pharmacology is still relatively sparse. To enable studies of the physiological roles governed by specific receptor and transporter subtypes, a series of GABA analogues comprising five-membered nitrogen- and sulfur-containing heterocycles as amine bioisosteres were synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors and GABA transporters. The dihydrothiazole and imidazoline analogues, 5 – 7, displayed moderate GAT activities and GABA A receptor binding affinities in the mid-nanomolar range ( K i, 90–450 nM). Moreover, they exhibited full and equipotent agonist activity compared to GABA at GABA A -αβγ receptors but somewhat lower potency as partial agonists at the GABA A -ρ 1 receptor. Stereoselectivity was observed for compounds 4 and 7 for the GABA A -αβγ receptors but not the GABA A -ρ 1 receptor. This study illustrates how subtle differences in these novel amino GABA bioisosteres result in diverse pharmacological profiles in terms of selectivity and efficacy.
No takes yet. Share an insight, caveat, or question.
Giraudo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: